contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


bioporto-indgar-partnerskab-med-beckman-coulter-om-ngal-tests-til-akut-nyreskade

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

CEO, Sweden

Claus Thestrup

BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel.

It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets. 

BioPorto

Selskabet annoncerer ny partnerskabsaftale med Beckman Coulter.

I g&#xe5;r annoncerede Bioporto endnu en distributionspartner til deres NGAL test. Distributionsaftalen g&#xe6;lder globalt og Beckman Coulter vil i f&#xf8;lge aftalen distribuere BioPortos neutrophil gelatinase-associated lipocalin (NGAL) tests til anvendelse p&#xe5; Beckman Coulters DxC/AU kliniske analyseinstrumenter.
I f&#xf8;rste omgang vil Beckman Coulter distribuere BioPortos NGAL tests i Europa efterfulgt af distribution i USA n&#xe5;r US Food and Drug Administration (FDA) har godkendt anvendelsen af ProNephro AKI&#x2122; (NGAL) til b&#xf8;rn p&#xe5; Beckman Coulters analyseinstrumenter. Aftalen kan udvides til at omfatte andre geografiske omr&#xe5;der.
Peter M&#xf8;rch Eriksen, Group CEO for BioPorto, udtaler: &#x201d;Indg&#xe5;elsen af aftalen med Beckman Coulter markerer en signifikant milep&#xe6;l i vores partnerskabsportef&#xf8;lje. Beckman Coulter er anerkendt for sine innovative analyseinstrumenter og sine evner til gnidningsfrit at integrere nye partnertests og teknologier p&#xe5; disse. BioPortos mission er at g&#xf8;re sundhedspersonale i stand til, at behandle de markante, uadresserede medicinske behov hos patienter med risiko for AKI. Ved at udvide vores distributionsnetv&#xe6;rk, styrke portef&#xf8;ljen af analyseinstrumenter, der kan arbejde med vores teknologi, og sikre samarbejder med ledende leverand&#xf8;rer af disse instrumenter, s&#xe6;tter vi os i en st&#xe6;rk position til at kunne accelerere adoptionen af vores test til vurdering af AKI. Partnerskabet med Beckman Coulter understreger den betydelige v&#xe6;rdi af vores teknologi og vores forpligtelse til at forbedre resultaterne for patienterne.&#x201d;
Indholdet af denne meddelelse p&#xe5;virker ikke BioPortos finansielle forventninger til 2024, som senest beskrevet i kvartalsregnskabet for andet kvartal 2024.
Bechman Coulter har i mods&#xe6;tning til Roche rendyrket fokus p&#xe5; diagnostik.
Disclaimer:&#xa0;HC Andersen Capital receives payment from Bioporto for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup&#xa0;8:30 AM 29-10-2024.

HC Andersen Capital

Bioporto: Indgår partnerskab med Beckman Coulter om NGAL Tests til akut nyreskade

Wall Streetin arvostustasoihin verrattuna Eurooppakin näyttää nyt houkuttelevalta

Federal Reserven korkopäätös: Kiire loppui tähän

Drug development investment: Value creation through M&As and licensing agreements

EKP:n korkopäätös: Keskuspankki ilman rajoitteita

Euroalueen ostopäälliköt: Onks sen jälkeen vielä mäki?

Login required

BioPorto

Stay up to date with our newsletter